Butorphanol: Effects of a Prototypical Agonist-Antagonist Analgesic, on κ-Opioid Receptors

DOI Web Site PubMed 被引用文献2件 参考文献130件
  • Commiskey Stephen
    Department of Pharmacology & Toxicology, University of Mississippi Medical Center
  • Fan Lir-Wan
    Department of Pharmacology & Toxicology, University of Mississippi Medical Center
  • Ho Ing K.
    Department of Pharmacology & Toxicology, University of Mississippi Medical Center
  • Rockhold Rob W.
    Department of Pharmacology & Toxicology, University of Mississippi Medical Center

書誌事項

タイトル別名
  • Butorphanol: Effects of a Prototypical Agonist-Antagonist Analgesic on .KAPPA.-Opioid Receptors
  • Butorphanol Effects of a Prototypical Agonist Antagonist Analgesic on カッパ Opioid Receptors

この論文をさがす

説明

The opioid analgesic, butorphanol (17-cyclobutylmethyl-3,14-dihydroxymorphinan) tartrate is a prototypical agonist-antagonist opioid analgesic agent whose potential for abuse has been the cause of litigation in the United States. With a published affinity for opioid receptors in vitro of 1:4:25 (μ:δ:κ), the relative contribution of actions at each of these receptors to the in vivo actions of the drug are an issue of active investigation. A body of evidence has been developed which indicates that a substantial selective action of butorphanol on the κ-opioid receptor mediates the development of tolerance to butorphanol and cross-tolerance to other opioid agonists; to the production of dependence upon butorphanol, particularly in the rodent; and to compensatory alterations in brain opioid receptor-effector systems. This perspective will identify the current state of understanding of the effects produced by butorphanol on brain opioid receptors, particularly on the κ-opioid receptor subtype, and on the expression of phosphotyrosyl proteins following chronic treatment with butorphanol.<br>

収録刊行物

被引用文献 (2)*注記

もっと見る

参考文献 (130)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ